COVID-19 vaccines: authorised

ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised

11 janvier 2021

An official website of the European UnionHow do you know?

Vaccines authorised in the European Union (EU) to prevent COVID-19, following evaluation by the European Medicines Agency (EMA).

EMA is not involved in advising on **travel requirements** in the EU, such as vaccination, quarantine or testing for travellers.

Decisions about which COVID-19 vaccines are included, for example, in the **EU Digital COVID Certificate**, are taken by the EU Member States. EMA is in charge of the scientific evaluation of vaccines for EU marketing authorisation. The acceptability criteria for travel purposes are broader and can include, for example, World Health Organization (WHO) listed vaccines that have not necessarily undergone the EMA process of authorisation.

Official information on this topic is available in all EU languages at:

- Re-open EU website and mobile app
- EU Digital Covid Certificate

Authorised COVID-19 vaccines

The following vaccines can be used in the EU to prevent COVID-19:

| Vaccine | Marketing authorisation holder | Key milestones | More information |
|--|--------------------------------------|---|--|
| Comirnaty (developed by BioNTech and Pfizer) | BioNTech Manufacturing GmbH | Conditional marketing authorisation issued: 21/12/2020 Annual renewal issued: 03/11/2021 | Latest news Safety updates Clinical data (login required) |
| | | 00/11/2021 | Paediatric investigation plan |
| COVID-19 Vaccine Janssen | Janssen-Cilag International NV | Conditional marketing authorisation issued: 11/03/2021 | Latest news Safety updates |
| | | Annual renewal application: under evaluation | Clinical data (login required) Paediatric investigation plan |

| Vaccine | Marketing authorisation holder | Key milestones | More information |
|---|--------------------------------------|--|-----------------------------------|
| Nuvaxovid | Novavax CZ, a.s. | Conditional marketing authorisation issued: 20/12/2021 | Latest news |
| Spikevax (previously COVID- 19 Vaccine Moderna) | Moderna Biotech Spain S.L. | Conditional marketing authorisation issued: 06/01/2021 | Latest news Safety updates |
| | | Annual renewal issued: 04/10/2021 | Clinical data (login required) |
| | | | Paediatric investigation plan |
| Vaxzevria (previously COVID- 19 Vaccine AstraZeneca) | AstraZeneca AB | Conditional marketing authorisation issued: 29/01/2021 | Latest news Safety updates |
| | | Annual renewal issued: 09/11/2021 | Clinical data (login required) |
| | | | Paediatric investigation plan |

Showing 1 to 5 of 5 entries

Previous1Next

For more information on how EMA evaluated these vaccines, see:

COVID-19 vaccines: Scientific evaluation and approval

Safety updates for authorised COVID-19 vaccines

EMA monitors the safety of COVID-19 vaccines authorised in the EU extremely carefully. This enables the detection of any **rare side effects** that may emerge once many millions of people are vaccinated.

Safety updates on each COVID-19 vaccine are available:

Safety of COVID-19 vaccines